Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05162443
Expanded Access Status : Available
First Posted : December 17, 2021
Last Update Posted : January 20, 2022
Information provided by (Responsible Party):
Mirati Therapeutics Inc.

Tracking Information
First Submitted Date December 3, 2021
First Posted Date December 17, 2021
Last Update Posted Date January 20, 2022
Descriptive Information
Brief Title Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Brief Summary The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Intermediate-size Population
Intervention Drug: adagrasib (MRTX849)
adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Early Access Care (EAC) (475) 522-2200
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT05162443
Current Responsible Party Mirati Therapeutics Inc.
Original Responsible Party Same as current
Current Study Sponsor Mirati Therapeutics Inc.
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators Not Provided
PRS Account Mirati Therapeutics Inc.
Verification Date January 2022